Try a new search

Format these results:

Searched for:

in-biosketch:true

person:bangas01

Total Results:

827


Percutaneous Coronary Intervention for Heart Failure due to Coronary Artery Disease

Singh, Arushi; Zhang, Robert S; Bangalore, Sripal
The role of revascularization and percutaneous coronary intervention (PCI) in patients with acute coronary syndrome is well established. However, the incremental value of revascularization over guideline-directed medical therapy is controversial. Currently available data supports the use of PCI to improve angina and quality of life for chronic coronary disease and heart failure (HF). However, there is insufficient data to support revascularization with PCI to improve mortality, reduce cardiovascular events, or improve ejection fraction over medical therapy alone. Additional trials are necessary to identify HF patients who may benefit from revascularization, and the optimal revascularization strategy for this population.
PMID: 43003527
ISSN: 2211-7466
CID: 6075753

Left atrial appendage closure, direct oral anticoagulants or warfarin in atrial fibrillation: a systematic review and network meta-analysis of randomised clinical trials

Pancholy, Samir; Maqsood, Muhammad Haisum; Saleem, Muhammad S; Zalavadia, Dipen; Khattar, Khyati; Patel, Tejas M; Bangalore, Sripal
PMID: 43003677
ISSN: 1468-201x
CID: 6075762

Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in ISCHEMIA-EXTEND

Hochman, Judith S; Anthopolos, Rebecca; Reynolds, Harmony R; Bangalore, Sripal; Xu, Yifan; O'Brien, Sean M; Boumakis, Stephanie; Chang, Michelle; Rosenberg, Yves; Senior, Roxy; Banfield, Ann; Goodman, Shaun G; Lopes, Renato D; Pracon, Radoslaw; Lopez-Sendon, Jose; Steg, P Gabriel; Maggioni, Aldo Pietro; Newman, Jonathan D; Berger, Jeffrey S; Sidhu, Mandeep S; White, Harvey D; Troxel, Andrea B; Harrington, Robert A; Boden, William E; Stone, Gregg W; Mark, Daniel B; Spertus, John A; Maron, David J; ,
IMPORTANCE/UNASSIGNED:It is unknown whether routine invasive management of chronic coronary disease improves long-term survival when added to guideline-directed medical therapy. OBJECTIVE/UNASSIGNED:To compare the effects of initial invasive and conservative strategies on long-term mortality in patients with chronic coronary disease. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:In this long-term follow-up study of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), an international trial of patients with chronic coronary disease, moderate or severe ischemia, left ventricular ejection fraction of 35% or more, and no left main coronary artery disease, unacceptable angina, or recent acute coronary syndrome, participants were randomized at 320 sites in 37 countries beginning August 2012 and followed up through December 2025. Data were analyzed using the intention-to-treat principle. INTERVENTION/UNASSIGNED:ISCHEMIA randomized patients to an initial invasive strategy of guideline-directed medical therapy plus coronary angiography and revascularization (when feasible) or an initial conservative strategy with guideline-directed medical therapy alone, with invasive management for failure of medical therapy. MAIN OUTCOMES AND MEASURES/UNASSIGNED:All-cause, cardiovascular, and noncardiovascular mortality were analyzed using cumulative incidence estimates, Cox and Fine-Gray models, bayesian analysis, and restricted mean survival time. RESULTS/UNASSIGNED:Among 5179 participants, median age was 64 (IQR, 58-70) years; 23% were female, 42% had diabetes, and median ejection fraction was 60% (IQR, 55%-65%). During 9-year median follow-up (range, 1 day to 13.4 years), 1071 deaths occurred (782 during extended follow-up): 672 cardiovascular, 359 noncardiovascular, and 40 unclassified. All-cause 11-year mortality was not significantly different between groups (25.8% invasive vs 26.9% conservative; estimated difference, -1.0 percentage point [95% CI, -4.2 to 2.1 percentage points]; adjusted hazard ratio [AHR], 0.97 [95% CI, 0.86-1.09]). By bayesian analysis, the posterior probability of more than 1 percentage-point survival benefit to invasive vs conservative was low (18%). Cardiovascular mortality at 11 years was 15.8% in the invasive group vs 17.1% in the conservative group (estimated difference, -1.4 percentage points [95% CI, -4.0 to 1.3 percentage points]; AHR, 0.88 [95% CI, 0.75-1.02]). Noncardiovascular mortality at 11 years was 9.1% in the invasive group vs 8.1% in the conservative group (estimated difference, 1.0 percentage point [95% CI, -0.9 to 2.9 percentage points]; AHR, 1.18 [95% CI, 0.96-1.45]). Eleven-year restricted mean survival was not significantly different (estimated difference, 14 days [95% CI, -41 to 70 days]). CONCLUSIONS AND RELEVANCE/UNASSIGNED:In this study, long-term all-cause mortality in patients with high-risk chronic coronary disease was not significantly different after routine invasive vs initial conservative management. TRIAL REGISTRATION/UNASSIGNED:ClinicalTrials.gov Identifier: NCT04894877.
PMID: 42998244
ISSN: 1538-3598
CID: 6075522

Percutaneous coronary intervention or medical therapy alone before transcatheter aortic valve replacement: insights from a meta-analysis of randomized trials

Mohamed, Ahmed Elmorsy; Abomohsen, Mustafa; Maqsood, Muhammad Haisum; Almakadma, Abdul Hakim; Kholeif, Zeyad; Gadelmawla, Ahmed Farid; Harari, Rafael; Kodali, Susheel K; Elgendy, Islam Y; Bangalore, Sripal
BACKGROUND:Coronary artery disease frequently coexists in patients undergoing transcatheter aortic valve replacement (TAVR), yet the benefit of routine percutaneous coronary intervention (PCI) before TAVR remains uncertain. OBJECTIVES/OBJECTIVE:To evaluate the efficacy and safety of routine PCI before TAVR compared with conservative or deferred revascularization. METHODS:We pooled randomized clinical trials comparing PCI before TAVR versus no/deferred PCI in patients with concomitant coronary artery disease. Random-effects models estimated pooled relative risks (RRs) with 95% confidence intervals (CIs). Bayesian sensitivity analyses and trial sequential analysis were performed. RESULTS:Three trials included 1156 patients (PCI, n = 579; no/deferred PCI, n = 577). In comparator arms reporting postrandomization PCI/revascularization, 72 of 461 patients (15.6%) underwent subsequent PCI/revascularization. PCI did not significantly reduce major adverse cardiac events (RR: 0.91, 95% CI: 0.70-1.18; I2 = 36.9%), myocardial infarction (RR: 0.86, 95% CI: 0.45-1.63; I2 = 49.8%), all-cause death (RR: 0.90, 95% CI: 0.70-1.15; I2 = 0.0%), or stroke (RR: 0.70, 95% CI: 0.48-1.03; P = 0.069; I2 = 0.0%). In two trials, PCI reduced urgent revascularization (RR: 0.33, 95% CI: 0.13-0.87; I2 = 54.5%) but increased major bleeding (RR: 1.57, 95% CI: 1.07-2.32; I2 = 37.9%) and any bleeding (RR: 1.77, 95% CI: 1.27-2.47; I2 = 66.7%). Bayesian analyses were directionally concordant. Trial sequential analysis was inconclusive for all efficacy outcomes. CONCLUSION/CONCLUSIONS:Routine PCI before TAVR reduced urgent revascularization but increased bleeding, without significant differences in other outcomes. Current evidence remains underpowered to rule out benefit for other ischemic outcomes; larger trials are needed.
PMID: 42973199
ISSN: 1473-5830
CID: 6075446

Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in Patients With Advanced Chronic Kidney Disease: ISCHEMIA-CKD EXTEND

Bangalore, Sripal; Maron, David J; Anthopolos, Rebecca; Reynolds, Harmony R; Xu, Yifan; Chang, Michelle; Boumakis, Stephanie; Lopez-Sendon, Jose; Senior, Roxy; Goodman, Shaun G; O'Brien, Sean M; Fleg, Jerome L; Hochman, Judith S; ,
BACKGROUND/UNASSIGNED:In the ISCHEMIA-CKD trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease), at a median follow-up of 2.2 years, the primary composite outcome of death or nonfatal myocardial infarction was similar between an initial invasive strategy (INV) compared with an initial conservative strategy (CON) in patients with moderate or severe myocardial ischemia and advanced chronic kidney disease. However, the long-term outcomes comparing the 2 strategies are unknown. METHODS/UNASSIGNED:Participants in the ISCHEMIA-CKD trial were randomly assigned to either INV, involving coronary angiography and revascularization when feasible, added to guideline-directed medical therapy or to CON with guideline-directed medical therapy alone and invasive procedures reserved for failure of guideline-directed medical therapy. After the active intervention trial phase, long-term vital status follow-up was conducted through participant contact by participating sites and by health record and centralized death database searches. The primary outcome for the extended follow-up phase was all-cause mortality. Secondary outcomes were cause-specific mortality, including cardiovascular and noncardiovascular mortality. RESULTS/UNASSIGNED:Among the 777 participants randomized (388 to INV and 389 to CON), over a median of 8 years of follow-up, vital status retention among survivors was 95%. There was a total of 429 deaths (55%). Cumulative all-cause mortality (57.4% versus 56.8%; adjusted hazard ratio, 1.05 [95% CI, 0.87-1.28]) or cardiovascular mortality (40.3% versus 38.4%; adjusted hazard ratio, 1.06 [95% CI, 0.84-1.34]) at 8 years did not differ between INV and CON. The restricted mean survival time was 1941 days (1834-2047 days) for INV versus 1990 days (1885-2094 days) for CON, with an adjusted estimated difference of -99 days (-245 to 46). The posterior probability of at least a 1 percentage point lower or higher death with INV at the 8-year median follow-up was 28% and 52%, respectively. Similarly, the posterior probability of at least a 1 percentage point lower or higher cardiovascular mortality with INV was 23% and 56%, respectively. CONCLUSIONS/UNASSIGNED:In patients with at least moderate ischemia and advanced chronic kidney disease, there was no significant long-term benefit of an initial INV at reducing the risk of all-cause or cardiovascular mortality compared with an initial conservative strategy. REGISTRATION/UNASSIGNED:URL: https://www.clinicaltrials.gov; Unique identifier: NCT01985360.
PMID: 42998238
ISSN: 1524-4539
CID: 6075521

Temporary Mechanical Circulatory Support in Pulmonary Embolism

Buda, Kevin G; Sharp, Andrew; Gundert, Emily; Bangalore, Sripal
This article highlights the limitations of thrombolysis in high-risk pulmonary embolism and the emerging role of temporary mechanical circulatory support, especially venoarterial extracorporeal membrane oxygenation, as a bridge to recovery or definitive therapy. The pathophysiology of right ventricular failure in pulmonary embolism, risk stratification strategies, and decision-making frameworks for initiating mechanical circulatory support are reviewed. Further, we cover practical considerations, including device selection, circuit management during thrombectomy, and the imperative for preanesthesia planning in risk mitigation. Finally, this article highlights the importance of conducting prospective and randomized studies on device choice, timing, and integration with reperfusion strategies.
PMID: 42977387
ISSN: 1557-8216
CID: 6075457

Sex-Specific Coronary Plaque Characteristics and Risk of Cardiovascular Events: Insights from ISCHEMIA

Lakshmanan, Suvasini; Wang, Yixin; Chen, Ying Qing; Mancini, Gb John; Leipsic, Jonathan; Budoff, Matthew; Hague, Cameron; Min, James K; Stone, Gregg W; Boden, William E; Spertus, John A; Bangalore, Sripal; Hochman, Judith S; Reynolds, Harmony R; Maron, David J; ,
Among the highly diseased population of participants with chronic coronary syndromes and obstructive coronary artery disease enrolled in the ISCHEMIA trial, women had lower burden of total, calcified, non-calcified plaque and adverse plaque characteristics on CCTA compared with men. However, the risk associated with greater atherosclerotic burden was higher among females for the composite outcome of CV death or MI than males. These findings highlight important sex-specific differences in the prognostic value of coronary atherosclerotic burden and support the need to explore differential approaches to cardiovascular risk stratification in men and women.
PMID: 42966435
ISSN: 1097-6744
CID: 6074827

Device-Specific Outcomes of Percutaneous Mechanical Aspiration in Right-Sided Infective Endocarditis: Insights From the Multicenter CLEAR-IE Registry

Robinson, Guy; Heybati, Kiyan; Hibbert, Benjamin; Bangalore, Sripal; Fong, Pete; Zlotnick, David; Zwischenberger, Brittany; Sayfo, Sameh; Younes, Stephanie; Ingrassia, Joseph; Hammadah, Muhammad; Prasad, Anand; Hamid, Nadira; Villablanca, Pedro; Kaki, Amir; Qintar, Mohammed; Patton, Marquand; Yucel, Evin; Yadav, Pradeep; Klein, Andrew; Baddour, Larry; Sorajja, Paul; Moriarty, John; Parikh, Sahil A; Sethi, Sanjum; El Sabbagh, Abdallah
PMCID:13591517
PMID: 42769534
ISSN: 2772-9303
CID: 6073509

Response by Bangalore et al to Letter Regarding Article, "Is There a Golden Hour for Thrombectomy in Intermediate-Risk Pulmonary Embolism? Insights From SYMPHONY-PE" [Letter]

Bangalore, Sripal; Bishay, Vivian
PMID: 42775440
ISSN: 1941-7632
CID: 6073532

Pooled Prasugrel Doses in a P2Y12 Network Meta-Analysis-Reply

Bangalore, Sripal; Maqsood, M Haisum; Kaul, Upendra
PMID: 42747814
ISSN: 2380-6591
CID: 6072910